The GLP-1 Story Nobody Is Telling

You’ve heard about it for two years.

The pharmacy commercials. The Instagram before-and-afters. The friend who lost forty pounds in five months and looks slightly different in the face. The cousin who swears she has never felt better. The cardiologist on the podcast saying it is the most important drug class of the decade. The wellness coach saying it is destroying women’s bodies. Your sister-in-law who is on it and your other sister-in-law who would never. The doctor’s appointment where you almost asked about it and then did not.

You have absorbed something you cannot quite articulate about GLP-1.

You know it is a class of drugs. You know Ozempic, Mounjaro and Wegovy are some of them. You know, there are thousands of knock-off, non-FDA approved versions being peddled. You know it suppresses appetite. You know it works. You also know there are concerns, although if someone asked you to name them you may have to think for a second.

What you have probably not heard, anywhere in this noise, is the part of the GLP-1 story that matters most for your body.

You have GLP-1.

You make it. You always have.

The drug everyone is talking about is a synthetic version of a hormone your own gut has been producing every time you have eaten a meal for your entire adult life. Ozempic, Wegovy, Mounjaro, and the others do not introduce something foreign to your body.

They mimic, amplify, and sustain a hormone you are already making.

The conversation about GLP-1 has been about a drug. The actual story is about a hormone you already have.

This means there is not one question to ask about GLP-1.

There are two.

And the women who are going to come out of this cultural moment leaner, stronger, and with their bodies intact are the women who figure out which question is theirs.

I am going to walk you through both.

GLP-1 stands for glucagon-like peptide-1. It is one of the most powerful hormones in your body, and it is made in a place nobody thinks to look.

Your gut.

Specifically, in cells called L-cells, which live in the lower part of your small intestine and your colon. When food reaches those cells, they release GLP-1 into your bloodstream.

The hormone then travels to multiple targets at once. It signals your pancreas to release insulin. It signals your brain that you are full. It slows down how fast food leaves your stomach. It quiets the hunger signals that tell you to eat more.

You have been doing this every time you have eaten a meal since you were a child.

You have never had to think about it. Your gut has been quietly running one of the most sophisticated metabolic and appetite-regulation systems in your body, and nobody felt it necessary to mention it to you, because nobody was selling you anything until now.

Here is what changes in midlife.

The L-cells in your gut do not disappear when we hit perimenopause.

They are still there. But three things make natural GLP-1 production less effective at doing what it used to do.

Your microbiome shifts. The bacteria in your gut influence how strongly your L-cells release GLP-1. As you age, and especially through menopausal hormonal changes, your microbiome diversity tends to decline. Less diverse microbiome means weaker L-cell signaling.

Your gut motility slows. Estrogen affects how quickly food moves through your gut. As estrogen drops, the timing of GLP-1 release shifts in ways that make the natural pulse smaller and less synchronized with your meals.

Your insulin response weakens. GLP-1 works partly by helping insulin do its job. In menopause, insulin resistance rises. The same amount of natural GLP-1 produces a smaller metabolic effect than it used to.

You are not making less GLP-1 because you are aging. You are making less effective GLP-1 because your gut is operating in a hormonal environment it has never been in before.

This is the part that almost nobody in the GLP-1 conversation is naming. Women in over 45 are not failing at appetite control. Their bodies are running a sophisticated system that has been quietly degrading for reasons that have nothing to do with willpower.

Notes from the Lab

The GLP-1 your body produces naturally lasts in your bloodstream for about two minutes. That is not a typo. Your L-cells release a pulse of GLP-1 after a meal, and within roughly 120 seconds, an enzyme called DPP-4 chops it apart. The signal is meant to be brief, sharp, and tied to eating.

The synthetic GLP-1 drugs like semaglutide and tirzepatide are resistant to DPP-4. They have been engineered to evade the enzyme that breaks down the natural version. Instead of lasting two minutes, the drug stays active for days. A single injection or daily oral dose produces a continuous, sustained GLP-1 signal that your body has never evolved to handle.

This is the part that nobody is correctly explaining.

These drugs are not just more GLP-1. They are GLP-1 doing something biologically different than what your gut does.

Your gut signals in pulses.

The drug signals in a continuous wave. Both produce weight loss. They do not produce the same thing in your body.

Once you understand that GLP-1 is something your body already makes, the question is not should I take the drug.

The question is what does my body need.

There are two paths. They are not in conflict. They are not pro or anti GLP-1. They are different starting places for different women, and the women who do well are the women who know which path is theirs.

If you are not on a GLP-1 drug, your gut still has the machinery to produce significant amounts of the hormone on its own. The L-cells in your lower gut respond to specific inputs from your diet, your microbiome, and your eating patterns.

A woman who supports her natural GLP-1 production correctly can produce meaningful appetite regulation, fullness signaling, and insulin response without ever touching the drug.

This is not biohacking or woo-woo.

This is using the system your body has been running for 45, 55, 65 years and giving it the inputs it needs to work the way it was designed to.

GLP-1 drugs work.

The clinical data is unambiguous. They produce sustained appetite suppression, meaningful weight loss, and metabolic improvements that most women cannot achieve with lifestyle changes alone.

What the clinical data also shows, and what the marketing does not tell you, is that the weight loss has a composition problem.

Of the total weight lost on GLP-1 drugs, somewhere between 25% and 40% is lean mass. Muscle. Bone. Connective tissue.

The body is shrinking everywhere, not just where the fat is.

For a menopausal woman, who is already losing muscle at an accelerated rate from estrogen withdrawal, this is not a side note. It is the central protection problem of the drug.

The internet has been arguing about whether to take GLP-1s. The real question is what to protect while taking them.

The hair shedding women report.

The facial fat and collagen loss that has been nicknamed “Ozempic face.”

The reports of weakness, exhaustion, and trouble lifting groceries six months in.

These are not random side effects. They are predictable consequences of significant rapid weight loss that includes substantial muscle and tissue loss, in a body that is also navigating menopausal hormonal shifts.

Path two is not wrong. It is the right path for many women.

But it is not a path you can walk passively. The drug works on you. You have to work back, or you come out of it leaner and weaker.

If you have talked to your doctor about GLP-1s and gotten anything other than here is the conversation about your body that has to happen before we make this decision, you are not alone.

The right questions are what is your body’s GLP-1 baseline doing, what is your muscle mass status going into this, what is your protein intake currently, what is your bone density, and what is your plan for the lean mass you are about to lose.

The drug is a tool.

The questions are the medicine.

Most women are getting the tool without the medicine.

This is what nobody has been telling you. The GLP-1 conversation has been a conversation about a drug. It needs to be a conversation about your body and what your body is doing right now.

Notes from the Lab

Research has shown that postmenopausal women who took semaglutide with hormone therapy lost significantly more weight than women who took semaglutide alone. At every checkpoint over twelve months, the HRT + GLP-1 women lost more, and lost more of it as fat rather than muscle.

What that study says, in plain language, is that the GLP-1 drug works better when the menopausal hormonal context is also being addressed. Which is another way of saying the drug does not exist in a vacuum. It works on a body, and the body it works on is hormonal, and the hormonal context determines whether the drug delivers what it promises or whether it delivers a hollower version of weight loss that takes more muscle than fat.

The drug is not a standalone answer. It is one input into a much larger conversation about what your body needs.

This is the question almost nobody is asking, and it is the only one that matters.

Where is your body right now?

Before you can decide whether to support your natural GLP-1 production or whether to take the drug and protect your body through it, you have to know what your body is doing.

How is your current appetite regulation? Are you hungry at predictable times or all the time? Does food fill you up or do you eat past full and not notice? When you eat protein, fiber, and starches, do you notice a difference in your fullness, or does nothing register?

How is your muscle mass right now? Can you carry groceries up two flights of stairs without burning out? Can you do five pushups? Can you stand up from a chair without using your hands?

How is your insulin sensitivity? Do you crash after carbs? Do you wake up between 2 and 4 a.m.? Has your waist measurement been moving even when your weight has not?

These are the questions that determine which path is yours.

And they are the questions almost no GLP-1 article on the internet, in either direction, is asking you to answer.

You cannot choose a path until you know where you are standing.

I am going to walk you through what each path actually looks like next, what the women who are doing well on each are doing differently, and where the wellness industry is steering you wrong on both.